Healwell AI Outlines Ambitious 2026 Targets Following Transformative Year

Following its recent earnings presentation for fiscal 2025, Canadian artificial intelligence firm Healwell AI has charted a detailed course for growth through 2026. The company, which has repositioned itself as a focused AI and software entity, reported record revenue alongside strategic objectives for the coming year.

Financial Performance: Record Revenue Amidst Transition Costs

Healwell AI closed its 2025 fiscal year with revenue soaring to $103.8 million. This figure represents a staggering 427% increase year-over-year, a surge primarily fueled by strategic acquisitions, including that of Orion Health. A significant milestone was achieved as the company reported its first full-year of positive adjusted EBITDA, which stood at $2.3 million.

However, the financial statement also reflected the costs associated with a corporate overhaul. The company posted an IFRS net loss of $39.1 million. As of the report date, Healwell held $18.6 million in liquidity. On the markets, its shares currently trade approximately 21% below their 200-day moving average, though they have recovered significantly from a low point recorded in February.

Strategic Growth Objectives for 2026

Management has set forth concrete targets for the upcoming year. These include achieving organic growth exceeding 50% within its AI and Data Science segment and securing 10% growth in recurring revenue from its healthcare software operations. Furthermore, the company aims to reach an adjusted EBITDA margin of approximately 10% by the end of 2026.

Should investors sell immediately? Or is it worth buying Healwell AI?

These ambitions are supported by recent commercial successes. In late February, Healwell secured its first contract with a government-operated health system in the Middle East. Shortly after, in early March, it landed a multi-year, multi-million dollar agreement with a U.S.-based Health Information Exchange. These deals signal growing international adoption of Healwell’s platform beyond its Canadian home market.

Portfolio Assets and Operational Roadmap

A notable item on the balance sheet drew investor attention during the earnings call. Healwell holds a $2 million stake in an investment vehicle that holds an interest in xAI, the artificial intelligence company founded by Elon Musk. Following the announced merger of xAI and SpaceX in February 2026, Healwell is evaluating potential options to monetize this holding. The company also holds minor stakes in several private healthcare technology firms, which are under similar review.

Operationally, key milestones are already defined. The North American launch of the Amadeus AI platform is scheduled for the first half of 2026, to be followed by an international expansion in the second half of the year. The execution of these launches will be a critical factor in determining whether the company’s margin targets are attainable.